Cannabinoids and autoimmune diseases: A systematic review

/by

Authors: Valeria Katchan, Paula David, Yehuda Shoenfeld
Autoimmunity Reviews, June 2016
—
Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess…

Read more

Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

/by

Authors: John M. McPartland, Geoffrey W. Guy, Vincenzo Di Marzo
PLoS One, 12 March 2014
—
BACKGROUND: The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology…

Read more

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

/by

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008
—
OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Read more